General Updates

AstraZeneca November 5, 2026 The Manager - Listing BSE Limited P J Towers, Dalal Street, Fort Mumbai - 400 001 The Manager - Listing National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex, Bandra (E) Mumbai - 400 051 Dear Sir/ Madam, Sub: Outcome of the Board Meeting held on Thursday, November 5, 2026 Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN Pursuant to Regulation 30 of the and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we hereby inform that at its meeting held today, i.e. on Thursday, November 5, 2026, the Board of Directors (‘Board’) has, inter alia, considered and approved the following: 1. Unaudited Financial Results The Unaudited Financial Results of the Company for the quarter and half – year ended September 30, 2026. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors are enclosed herewith. Further, we are arranging to publish the above-mentioned financial results in newspapers as per Regulation 47 of the SEBI Listing Regulations. 2. Appointment of Mr. Krishnamurthy Narayanan Iyer as an Additional Director (Independent) of the Company Based on the recommendation of the Nomination and Remuneration Committee (‘NRC’), the Board has approved the appointment of Mr. Krishnamurthy Narayanan Iyer (DIN: 01726564) as an Additional Director of the Company with effect from November 5, 2026, to hold office as a Non- Executive, Independent Director, not liable to retire by rotation, for a term of five (5) consecutive years, subject to approval of the shareholders of the Company. CORPORATE & REGO. OFFICE TEL : +91 80 6774 8000 FACTORY TEL : +918067749000 AstraZeneca Pharma India Ltd. 12th Mile on Bellary Road P. B. No. 4525, Block N1, 12th Floor, FAX : +91 80 6774 8857 Venkatala, Kattigenahalli Village Manya ta Embassy Business Park, CIN : L24231KA1979PLC003563 Yelahanka FAX : +91 80 2846 2208 Rachenahalli, Outer Ring Road, Bangalore -560 063 +91 80 677 4 9628 Bangalore -560 04 5, INDIA WEB : www.astrazeneca.com/india INDIA AstraZeneca 3. Appointment of Mr. Atul Tandon as Chief Financial Officer of the Company Based on the recommendation of the NRC and the Audit Committee, the Board has approved the appointment of Mr. Atul Tandon as Chief Financial Officer (i.e. a Key Managerial Personnel as defined in the Companies Act, 2013), with effect from November 9, 2026. 4. Change in designation of Mr. Nitin Bindal (Senior Management Personnel) to Director - Biopharmaceuticals Business Unit Further to our communication dated January 9, 2026, intimating about the appointment of Mr. Nitin Bindal as Director - Institutional Business & Public Channels, we hereby inform about a change in his role to Director - Biopharmaceuticals Business Unit, with effect from November 9, 2026. Mr. Bindal continues to be a Senior Management Personnel of the Company. Consequent to this role change, the Institutional Business and Public Channel functions, will revert to the Oncology Business Unit. 5. Appointment of Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit Based on the recommendation of the NRC, the Board has approved the appointment of Mr. Kumaran Krishnan as Medical Director - Biopharmaceuticals Business Unit (Senior Management Personnel) with effect from December 1, 2026. The details for the above appointments / change in SMP role as required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure - A. The above information is also being made available on the website of the Company at www.astrazeneca.com/india. The meeting of the Board of Directors commenced at 1.30 p.m. and concluded at 3.50 p.m. Kindly take the above information on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No. A25784 CORPORATE & REGO. OFFICE TEL : +91 80 6774 8000 FACTORY TEL : +918067749000 AstraZeneca Pharma India Ltd. 12th Mile on Bellary Road P. B. No. 4525, Block N1, 12th Floor, FAX : +91 80 6774 8857 Venkatala, Kattigenahalli Village Manya ta Embassy Business Park, CIN : L24231KA1979PLC003563 Yelahanka FAX : +91 80 2846 2208 Rachenahalli, Outer Ring Road, Bangalore -560 063 +91 80 677 4 9628 Bangalore -560 04 5, INDIA WEB : www.astrazeneca.com/india INDIA AmllZeneca Pbarm■ India Limited Regd. Office : Block NI, 12th Floor, Manya ta Embauy Buslnen Park, Racbenaballl, Outer Ring Road, Bangalore 560 045 CIN: L24231KAl979PLC003S63 Statement of unaudited financial results for the quarur and half year ended 30th September 2026 'RI in mJlllom eu:ent for eaminas ner share data SI No. Parllculan Quarter ended Half""ear ended Year ended 30-09-2026 30-06-2026 30-09-2025 30-49-2026 30-09-2025 3Ul3-2016 1JJwulJud llilaodlted Unaudited Unaucllted Unaucllted Audited 1 Income a) Revenue from operations 7,291.0 6,827.9 5,590.9 14,118.9 10,854.0 22,755 8 b) Other income 151.2 92.3 61.7 243.5 174.1 284.9 Total Income 7,442.2 6,920.1 5,652.6 14,362.4 11,028.1 23,040.7 2 . . (a) Cost of materials consumed 94.9 94.9 (b) Purchase of stock-in-trade 6,241 0 3,046.2 4,324.0 9,287.2 8,499.9 18,594.2 (c) Changes in inventori°" offiniohed goods, (1,502.5) 1,425.9 (1,079 I) (76.6) (2,395.8) (4,883.7) worli:.-in rogres, aod stock-io-trade (cl) Employee benefit expense 678.5 791.6 604.S 1,470.1 1,249.0 2,643.8 (e) Finance costs 18.9 19.5 6.7 38.4 13.9 44.9 (f) Depreciation and amortisation expense 53.5 52.3 25.7 l05,8 191.4 285.8 (g) Selling, marl<eting and distribution expense 177.0 307.5 280.l 484.5 500.3 1,160.0 (b) Other expense, 741.3 767 3 709.6 1,508.6 1,342.8 2,526.3 Total eipenses 6,407.7 6,410.3 4,871.5 12,818.0 9,496.4 20,466.2 3 Protll before euepllonal Item■ and tu( 1-2) 1,034.5 509.9 781.1 1,544.4 1,531.7 2,574.5 4 Add/(Less): Exceptional items (Refer Note 3,4,5) (149,6) (2.4) (52.9) (152.0) (56.5) (S2.5) 5 Proftt before tax (3+4) 884.9 507.S 728.2 1,392.4 1,47!1.2 2,522.0 6 Tuespense ( a) Current tax 250..3 10-8 7 19-0.l 35-9.0 41 -1.1 591.4 (b) Tax cxpcmc for prior ycan 2.8 {c) Deferred tax chnge / (credit) 11.3 19.5 (4.1) 30.8 (36.4) 52.6 Total tu: Hpense (net) 261.6 128.2 186.0 389.8 374.7 646.8 7 Profit after tu {S-6) 623.J 379.J 542.2 1,001.6 1,100.5 1,875.2 8 Other comprehemive {Ion)/ Income ltenu that will not be reclassified to profit or loss (a) Re-measurement (losses)/ gsins on post employment benefit (3.7) {4.0) (4.1) (7.7) 4.l (59.4) obligatioos (b) Income tax effect on above 0.9 1.0 I.I l.9 (1.0) 15.0 Other compreben1ive {1011)/ lncome,net of Income tu (2.8) (3.0) (3.0) (5.8) 3.1 (44.4) 9 Total comprehemlve Income for the period/ year (7+8) 620.5 376.J 539.2 996.8 1,103.6 1,830.8 10 Paid-up eqaJty 1han capital 50.0 50.0 50.0 50.0 50.0 50.0 (Face value oFRs 1J-per equity share) - . . . II Other Equity 8,677.9 12 Earnings per equity share of lb 2/-each (basic and diluted) 24.93* 15.17* 21.69* 40.10* 44.02* 75.01 *Not ■Jlllualiscd AstraZeneca Pharma India Limited Statement of unaudited assets and liabilities Rs in mllU001 SI.No. Balance Sheet AJ at 30--09-2026 31-03-2026 Unaudited Audited ASSETS 1 Non-current assets (a) Property, plant and equipment 31.2 46.7 (b) Right-of-use assets 959.3 1,128.0 (c) Capital work-in-progress 155.9 . ( d) Financial Assets (i) Other financial assets 113.7 134.1 (e) Non-Current tax assets (net) 888.1 789.2 (f) Deferred tax assets (net) 349.3 378.0 (g) Other non-current assets 14.2 15.7 Total Non-current aS1ets 251L7 2.491.7 2 Current assets (a) Inventories 10,350.0 10,273.3 (b) Financial Assets (i) Trade receivables 2,850.0 2,136.8 (ii) Cash and cash equivalents 5,738.1 4,477.2 (iii) Banlc balances other than cash and cash equivalents 13.3 9.0 (iv) Loans - (v) Other financial assets 114.4 87.4 (c) Other current assets 300.4 338.2 Total Current assets 19,366.2 17,321.9 3 Alisets classified u held for sale (Refer [Showing first 8,000 characters — download PDF for full document]